We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Automating Blood Smears Developed for Easier Malaria Diagnosis

By LabMedica International staff writers
Posted on 03 Feb 2022
Blood smears are used in diagnosis for a variety of hematological disorders, such as anemia and leukemia. More...
They are also the preferred method of diagnosis of parasitic infections, such as malaria and filariasis in developing world laboratories.

The current “gold standard” for malaria diagnosis is by optical microscopy examination of blood smears. A thin film of the patients’ bloods is fixed onto a microscope slide and stained. The microscopists look at the smear, counting the parasites in various fields of view. These experts can establish the species of malaria and parasite density.

Bioengineers at Cambridge University (Cambridge, UK) collaborating with their colleagues in Tanzania and the UK created a series of devices, which they call “autohaem.” Autohaem devices aim at enabling even non-experts to produce consistent, high quality, thin film blood smears at low cost. The autohaem devices, solves this problem by automating the smearing process so every smear is correct and consistent. The devices come in two varieties, the autohaem smear and the autohaem smear+, the latter of which is fully automated with a motorized smearing mechanism. In tests, inexperienced technicians were able to use the device to produce expert-quality smears.

A key goal of the project was to make the devices accessible to as many people as possible, so the scientists designed their devices to be easy to build, using readily available or 3D-printed components. A pipeline for automated analysis of smear quality was presented and used for device optimization. Red Blood Cells (RBCs), at the typical hematocrit for malaria investigations, are used as the testing media. This pipeline will also be suitable for a more systematic analysis of blood smear preparation, for example, to help with training and evaluation of technicians.

Samuel McDermott, PhD, the senior author of the study, said, “Creating blood smears is a laborious, repetitive task that requires an expert level of skill and manual dexterity. By using automated blood smearing machines, such as autohaem devices, technicians will be able to increase their throughput while maintaining a high enough quality for diagnosis. In some countries, up to 81.5% of blood smears are prepared incorrectly. If a blood smear is prepared incorrectly, when examined under a microscope, the technician will struggle to make a correct diagnosis. Because these smears are often made in a rural clinic and sent to a regional facility for examination, any issues in the smear could cause days of delay.”

The authors concluded that they have developed and presented the autohaem range of devices for automated blood smearing. Autohaem smear is a mechanical device, and autohaem smear+ is an electro-mechanical device. The devices are designed to be sustainable and all the designs and assembly instructions are available under an open source license. The study was published on January 18, 2022, in the journal Review of Scientific Instruments.

Related Links:
Cambridge University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hematology Consumables
Bioblood Devices
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.